4.5 Article

Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease

Journal

JOURNAL OF ALZHEIMERS DISEASE
Volume 58, Issue 3, Pages 909-918

Publisher

IOS PRESS
DOI: 10.3233/JAD-170073

Keywords

Alzheimer's disease; biomarkers; cerebrospinal fluid; episodic memory; mild cognitive impairment; mild neurocognitive disorder; neuropsychological test

Categories

Funding

  1. Carlos III Institute of Health, Spain [PI11/02425, PI14/01126, PI10/1878, PI13/01532, PI11/03035, PI14/1561]
  2. CIBERNED program - Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
  3. Marato TV3 grant [20141210]
  4. Generalitat de Catalunya [2014SGR-0235]
  5. i-PFIS from the FIS, Instituto de Salud Carlos III [IF15/00060]
  6. Carlos III Institute of Health, Spain [PI11/02425, PI14/01126, PI10/1878, PI13/01532, PI11/03035, PI14/1561]
  7. CIBERNED program - Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, Una manera de hacer Europa
  8. Marato TV3 grant [20141210]
  9. Generalitat de Catalunya [2014SGR-0235]
  10. i-PFIS from the FIS, Instituto de Salud Carlos III [IF15/00060]

Ask authors/readers for more resources

Background: Episodic memory impairment is the core feature of typical Alzheimer's disease. Objective: To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d). Methods: Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/A beta(1-42) ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model. Results: A total of 202 MCI patients with a mean follow-up of 34.2 +/- 24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-AD patients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test. Conclusions: The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available